Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 4:53 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 5,320 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Continuous Dose Clear all
Not yet recruiting Phase 2 Interventional

RiMO-HNC-NEO1: Phase 2 Study of RiMO-301 and Hypofractionated Radiotherapy With Pembrolizumab for the Neoadjuvant Treatment of Resectable, Locally Advanced Head-Neck Cancer

NCT07732634
View directory record Official record
Conditions
Head and Neck Cancer, Head Cancer, Neck Cancer
Interventions
RiMO-301, Pembrolizumab, Radiation, Surgical resection
Drug · Radiation · Procedure
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Nov 3, 2026, 4:53 AM EST
Completed Not applicable Interventional

Pain Relief Effects on Length of Labor

NCT01750099
View directory record Official record
Conditions
Labor Pain
Interventions
Combined Spinal-epidural, Continuous Lumbar epidural
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
16 Years to 44 Years · Female only
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2014 · Synced Nov 3, 2026, 4:53 AM EST
Completed Phase 2Phase 3 Interventional Results available

Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer

NCT04082364
View directory record Official record
Conditions
Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer
Interventions
margetuximab, Retifanlimab, Tebotelimab, Trastuzumab, Chemotherapy
Biological · Other
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
28
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Nov 3, 2026, 4:53 AM EST
Completed Phase 3 Interventional Results available

Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity

NCT02896192
View directory record Official record
Conditions
Pro-opiomelanocortin (POMC) Deficiency Obesity
Interventions
Setmelanotide, Placebo
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
6 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Nov 3, 2026, 4:53 AM EST
Completed Phase 2 Interventional Results available

Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options

NCT03583164
View directory record Official record
Conditions
Invasive Fungal Infections
Interventions
Olorofim
Drug
Lead sponsor
F2G Biotech GmbH
Industry
Eligibility
16 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
14
States / cities
Bakersfield, California • Sacramento, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Nov 3, 2026, 4:53 AM EST
Completed Phase 4 Interventional Results available

Effectiveness of Methylphenidate in Improving Cognition and Function in Older Adults With Depression

NCT00602290
View directory record Official record
Conditions
Depression
Interventions
Citalopram, Methylphenidate (MPH), Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
60 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Nov 3, 2026, 4:53 AM EST
Completed Phase 1 Interventional

Oxaliplatin and Topotecan in Treating Patients With Previously Treated Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

NCT00006391
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
oxaliplatin, topotecan hydrochloride
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2011 · Synced Nov 3, 2026, 4:53 AM EST
Recruiting Phase 4 Interventional

Immune Modulation During Palynziq® Treatment in Adults (IMPALA)

NCT07477691
View directory record Official record
Conditions
Phenylketonuria
Interventions
Pegvaliase, Methotrexate
Biological · Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
12
States / cities
Los Angeles, California • Aurora, Colorado • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Nov 3, 2026, 4:53 AM EST
Completed Phase 3 Interventional Results available

Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia

NCT02716818
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
Chronocort®, standard glucocorticoid therapy
Drug
Lead sponsor
Neurocrine UK Limited
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Nov 3, 2026, 4:53 AM EST
Recruiting Phase 1 Interventional

Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS

NCT06096974
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
YL-17231
Drug
Lead sponsor
Shanghai YingLi Pharmaceutical Co. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Cincinnati, Ohio • Houston, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Nov 3, 2026, 4:53 AM EST
Completed Phase 1 Interventional

Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma

NCT03535350
View directory record Official record
Conditions
Glioblastoma
Interventions
Ibrutinib, Radiation, Temozolomide (TMZ)
Drug · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 3, 2026, 4:53 AM EST
Recruiting Phase 2 Interventional

The CATSINDO Trial - Clinical and Translational Study in Newly Diagnosed Osteosarcoma

NCT07560826
View directory record Official record
Conditions
Osteosarcoma in Children, Osteosarcoma in Adolescents and Young Adults
Interventions
High-dose Methotrexate
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
7 Years to 22 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
9
States / cities
Chapel Hill, North Carolina • Charlotte, North Carolina • Durham, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 3, 2026, 4:53 AM EST
Completed Phase 1 Interventional

Continued Access to RXDX-105

NCT03784378
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Ovarian Cancer, RET Gene Mutation, BRAF Gene Mutation
Interventions
RXDX-105
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Nov 3, 2026, 4:53 AM EST
Terminated Phase 1 Interventional Results available

This Is The First Study Using Escalating Doses Of PF-03758309, An Oral Compound, In Patients With Advanced Solid Tumors

NCT00932126
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
PF-03758309
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Santa Monica, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Nov 3, 2026, 4:53 AM EST
Completed Phase 3 Interventional Results available

Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension

NCT03187678
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
i.v. selexipag, oral selexipag (Uptravi)
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
La Jolla, California • Boston, Massachusetts • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Nov 3, 2026, 4:53 AM EST
Recruiting Phase 3 Interventional

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

NCT07577843
View directory record Official record
Conditions
Crohn Disease
Interventions
JNJ-78934804, Guselkumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
22
States / cities
Anaheim, California • Chula Vista, California • Los Alamitos, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Nov 3, 2026, 4:53 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Feasibility Study Assessing the Ability of an Insulin Pump-controlling Algorithm to Minimize Hypoglycemia

NCT01919385
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Predictive Low Glucose Minimizer
Device
Lead sponsor
Animas Corporation
Industry
Eligibility
21 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Nov 3, 2026, 4:53 AM EST
Terminated Early Phase 1 Interventional

Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors

NCT03454243
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors
Interventions
RXDX-106
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Nov 3, 2026, 4:53 AM EST
Completed Phase 2 Interventional Results available

Intraoral Administration of Botox in Patients With Dentoalveolar Neuropathic Pain

NCT03848143
View directory record Official record
Conditions
Neuropathic Pain
Interventions
onabotulinum toxin A
Drug
Lead sponsor
Isabel Moreno Hay
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Nov 3, 2026, 4:53 AM EST
Not listed Phase 4 Interventional

US-guided SAPB for Rib Fractures in the ED

NCT03619785
View directory record Official record
Conditions
Rib Fractures, Rib Fracture Multiple
Interventions
Bupivacaine, Fentanyl, morphine, hydromorphone, hydrocodone, acetaminophen, ketorolac, gabapentin, ketamine, ibuprofen
Drug
Lead sponsor
Andrew A Herring
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Nov 3, 2026, 4:53 AM EST
Completed Phase 2 Interventional Results available

Extension Study to Assess the Efficacy and Safety of Repeat Treatment With Rituximab (MabThera) in Participants With Active Rheumatoid Arthritis (RA)

NCT02093026
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Rituximab, Methotrexate, Methylprednisolone, Folic Acid
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
21 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
42
States / cities
Birmingham, Alabama • Peoria, Arizona • Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Nov 3, 2026, 4:53 AM EST
Completed Phase 2 Interventional Results available

A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM)

NCT02139943
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
25 Years to 65 Years
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
46
States / cities
Little Rock, Arkansas • Concord, California • La Jolla, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Nov 3, 2026, 4:53 AM EST
Completed Phase 1 Interventional Results available

First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors

NCT01609556
View directory record Official record
Conditions
Tumors
Interventions
Mirvetuximab soravtansine
Drug
Lead sponsor
ImmunoGen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
10
States / cities
Fairway, Kansas • Boston, Massachusetts • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Nov 3, 2026, 4:53 AM EST
Active, not recruiting Phase 3 Interventional Results available

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

NCT04232553
View directory record Official record
Conditions
Crohn's Disease
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
996 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
54
States / cities
Dothan, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Nov 3, 2026, 4:53 AM EST